News List

Indo-US agree on five-year extension of Vaccine Action Program


A Joint Statement for extension of VAP program for a period of five years till 2022 was signed between Prof. K. Vijay Raghavan, Secretary DBT and Dr. Anthony S. Fauci, Director, NIAID, NIH, USA.

By Team ABLE

At the recently held 29th Joint Working Group meeting of the Vccine Action Program signed by USA and India, Dr Anthony S Fauci, Director of National Institute of Allergy and Infectious Diseases (NIAID) delivered the Rama-Robbins lecture. The meeting was held on April 11-12, 2017 at NIAID, NIH, USA.

During the two-day meeting a Joint Statement for extension of VAP program for a period of five years till 2022 was signed between Prof. K. Vijay Raghavan, Secretary DBT and Dr. Anthony S. Fauci, Director, NIAID, NIH, USA.

The Department of Biotechnology is implementing a bilateral program called Indo-US Vaccine Action Program, (VAP) with National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services (DHHS), USA since July, 1987. The program supports a broad spectrum of activities relating to new and improved vaccines.

The program was designed to encompass laboratory-based research, evaluation of candidate vaccine development, testing for clinical development, vaccine quality control, delivery of vaccines etc. All work is carried out within areas designated as VAP priorities by the VAP Joint Working Group (JWG) which is composed of eminent scientists and policymakers from both the countries.